Johnson & Johnson (JNJ)
Johnson & Johnson makes prescription medicines and medical devices for hospitals, doctors and eye care professionals. It last closed at $278.75 on Nov 17, down 1.34% on the day. JNJ reports earnings on Tue, Jan 26, 2027. The average 12-month price target from 8 analysts is $294.88 (+5.8% from the last close), with a high of $320.00 and a low of $272.00. Analyst consensus is Strong Buy, based on the latest ratings from 8 firms (7 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 5 whale options trades in JNJ, 60% of them bullish and 40% bearish. In the past 30 days there were 51 dark pool prints totaling $74.2M, the largest $20.0M. FLEX reports show 2 notable institutional FLEX trades in JNJ, totaling $12.5M in premium, the latest on Oct 29.
Key Stats
Last 12 monthsNot reported for this period.
From JNJ's SEC filings, latest 10-Q for the period ending Sep 27, 2026 (filed Oct 21). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 8 analysts who set a price target on JNJ in the past 90 days. The average target is $294.88, with a high of $320.00 and a low of $272.00, compared with the last close of $278.75.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 16 | Wells Fargo | Target raised | Buy | $275 → $287 |
| Oct 15 | Morgan Stanley | Target lowered | Buy | $294 → $292 |
| Oct 14 | Leerink Partners | Target raised | Buy | $265 → $272 |
| Oct 14 | Wells Fargo | Target lowered | Buy | $282 → $275 |
| Oct 14 | RBC Capital | Target lowered | Buy | $290 → $280 |
Technical Analysis
The stock is 2% above its 20 day and 4% above its 50 day average. It is 10% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 56). The nearest support is the Pivot S1 at $276.97, and the nearest resistance the Pivot at $279.34.
| RSI (14) | 56.49 | Middle of its range | Neutral |
| MACD | 5.09 | Above its signal line | Bullish |
| Stochastic | 71.5 | Middle of its range | Neutral |
| ADX (14) | 25.9 | Trending up | |
| Williams %R | -46.1 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 58.7 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +4.7% | Change over 10 sessions | Bullish |
| ATR (14) | $6.76 | Typical daily range, 2.4% of price |
| RSI (14) | 60.62 | Strong, overbought above 70 | Neutral |
| MACD | 9.69 | Above its signal line | Bullish |
| Stochastic | 84.4 | Near the top of its range | Overbought |
| ADX (14) | 30.0 | Trending up | |
| Williams %R | -25.5 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 152.5 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +5.0% | Change over 10 sessions | Bullish |
| ATR (14) | $13.79 | Typical daily range, 5.0% of price |
What happened before
See how JNJ did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How JNJ has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in JNJ in the last 90 days.
Dark Pool
30DFLEX Options Activity
FLEX Flow →FLEX options are customized, exchange-listed contracts used mostly by institutions. StreetAlpha scans the daily FLEX report for unusually large, long-dated positions. Multi-leg structures, such as paired calls and puts used for financing or hedging, are listed but not counted in these totals.
JNJ Institutional Ownership
Full report →- ●2,068 buying vs 1,996 selling
- ▼Held by funds -1.8 pts
- ●Funds holding +10
- ▼Superinvestors: 1 added, 2 cut
- ▲Put/call 1.32 to 1.01
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 4,711 | 4,701 | +0.2% |
| In funds' top 10 | 323 | 296 | +9.1% |
| Held by funds | 73.6% | 75.4% | −1.8 pts |
| New / increased | 169 / 1,899 | 154 / 1,955 | −1.9% |
| Reduced / sold out | 1,895 / 101 | 1,863 / 120 | +0.7% |
| Put/call ratio | 1.01 | 1.32 | −23.3% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
JNJ Stock Buybacks
See all S&P 500 buybacks →From the company's 10-Q filed Oct 21, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether JNJ is in one of them and how their past JNJ trades turned out.
JNJ News Tone and Price
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered JNJ in an article yet. Here's the latest on the wider market.
JNJ Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Ro KhannaD · CA | Sell | $100K – $250K | Oct 7, 2026 | Nov 9, 2026 | 33 d |
| Ro KhannaD · CA | Sell | $50K – $100K | Oct 7, 2026 | Nov 5, 2026 | 29 d |
| Thomas KeanR · NJ | Sell (partial) | $1K – $15K | Sep 30, 2026 | Oct 30, 2026 | 30 d |
| Ro KhannaD · CA | Buy | $1K – $15K | Sep 25, 2026 | Oct 7, 2026 | 12 d |
| Ro KhannaD · CA | Buy | $15K – $50K | Sep 4, 2026 | Oct 7, 2026 | 33 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Johnson & Johnson
Johnson & Johnson is a healthcare company based in New Brunswick, New Jersey, that researches, makes and sells medicines and medical devices. Its Innovative Medicine business offers prescription drugs for conditions such as cancer, immune disorders, mental health conditions, HIV and pulmonary arterial hypertension. Its MedTech business supplies products for heart care, surgery, orthopaedic procedures and vision care. Its customers include hospitals, doctors, retailers, wholesalers and eye care professionals, and it sells in virtually all countries.
- Headquarters
- New Brunswick, NJ
- Founded
- 1886
- Website
- jnj.com ↗









